Google
CNTA — CENTESSA PHARMACEUTICALS PLC ADR (Healthcare >> Biotechnology)
CNTA FAQ
What is CNTA's ROE?
CENTESSA PHARMACEUTICALS PLC ADR reports a Return on Equity (ROE) of -51.43%.
What is CNTA's dividend yield?
CENTESSA PHARMACEUTICALS PLC ADR offers a dividend yield of 0.00%.
What is CNTA's Deepscope Quality Score?
Deepscope rates CNTA's overall financial quality at 15 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy CNTA?
Deepscope's AI Timing Score for CNTA is 87 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does CNTA belong to?
CENTESSA PHARMACEUTICALS PLC ADR is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 39.69
Price
-0.07
(-0.18%)
Day Change
|
|
|---|
CNTA, the overall quality is not good ( Quality = 15) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 83 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 39.69 |
| PBV / Sector |
12.62 / 4.79
|
| Earning Per Share | -1.62 |
| PE / Sector |
N/A / 17.89
|
| PEG or PE/Growth / Sector |
N/A / 0.56
|
| Average 1M Daily Value |
48.61 M
GREAT
|
| Average 1W Daily Value |
65.63 M
|
| Timing Factors |
|
57% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
47% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-11 09:54:30 |
| Symbol | CNTA |
| Name | CENTESSA PHARMACEUTICALS PLC ADR |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 154.73 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 6,152.02 / 8,963.32 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1 Ashley Road, Altrincham, United Kingdom, WA14 2DT
Phone: 44 617 4685770
Website: https://centessa.com
Employees: 129
Sector: Healthcare >> Biotechnology
Description: Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersomnia. It also engages in the development of ORX142 which is in Phase I clinical trial for the treatment of neurological and neurodegenerative disorders; ORX489 which is in Phase I clinical trial for the treatment of neuropsychiatric disorders; and LockBody, an early-stage immuno-oncology program technology platform. The company was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
